论文部分内容阅读
目的了解以克力芝为基础的初始抗病毒治疗方案,对成人艾滋病病毒(HIV)感染者/艾滋病(AIDS)病人(简称HIV/AIDS病人)血脂的影响。方法回顾性分析2010年10月至2015年10月间,北京佑安医院以克力芝作为初始抗病毒治疗药物的106例HIV/AIDS病人的血清总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL)、高密度脂蛋白(HDL)以及TC/HDL比值的数据,比较抗病毒治疗前后血脂的变化特点。结果 106例HIV/AIDS病人抗病毒治疗前总的血脂异常率为74.5%,其中TG、TC、HDL、LDL和TC/HDL异常的HIV/AIDS病人百分比分别为31.1%、9.4%、49.1%、6.6%和18.9%;抗病毒治疗后总的血脂异常率为89.6%,TG、TC、HDL、LDL和TC/HDL异常HIV/AIDS病人的百分比分别为63.2%、16.0%、56.6%、5.7%和21.7%。与基线比较,TG升高的HIV/AIDS病人比例从31.1%到63.2%(P<0.001),且其数值水平中位数从1.2mmol/L升高到1.93mmol/L(P<0.001);TC在治疗后数值中位数从4.06mmol/L升高到4.32mmol/L,但异常HIV/AIDS病人百分比的变化无统计学意义(P>0.001);作为动脉粥样硬化性心血管疾病(ASCVD)最重要的预警指标的LDL,在治疗后并没有升高。结论以克力芝为基础的初始抗病毒治疗方案可以影响病人的血脂代谢,但仅对TG和TC的影响比较明显,而对于ASCVD最主要危险因素的LDL的影响较小。
Objective To understand the effect of Keli-based initial antiviral treatment on blood lipids in adults with HIV / AIDS (AIDS / AIDS). Methods The total cholesterol (TC), triglyceride (TG) and total cholesterol (TC) were determined in 106 HIV / AIDS patients who were treated with Kelixi as the initial antiviral drug from October 2010 to October 2015 in Beijing You’an Hospital. , Low density lipoprotein (LDL), high density lipoprotein (HDL) and TC / HDL ratio data were compared before and after anti-viral treatment of blood lipid changes. Results The total rate of dyslipidemia before anti-virus treatment in 106 HIV / AIDS patients was 74.5%. The percentage of HIV / AIDS patients with abnormal TG, TC, HDL, LDL and TC / HDL were 31.1%, 9.4%, 49.1% 6.6%, and 18.9% respectively. The total rate of dyslipidemia after anti-virus therapy was 89.6%, and the percentage of HIV / AIDS patients with abnormal TG, TC, HDL, LDL and TC / HDL were 63.2%, 16.0%, 56.6% And 21.7%. Compared with the baseline, the proportion of HIV / AIDS patients with TG increased from 31.1% to 63.2% (P <0.001), and the median increased from 1.2 mmol / L to 1.93 mmol / L (P <0.001). TC median after treatment increased from 4.06mmol / L to 4.32mmol / L, but the percentage of abnormal HIV / AIDS patients had no significant change (P> 0.001); as atherosclerotic cardiovascular disease ( ASCVD) The most important predictor of LDL did not rise after treatment. Conclusion The initial antiviral treatment regimen based on ganoderma lucidum could affect the blood lipid metabolism of patients, but it has obvious effects on TG and TC only, but has little effect on LDL, which is the most important risk factor of ASCVD.